Karman Holdings, Inc. (NYSE: KRMN) — A Real Merchant-Supplier Moat, Priced as If Golden Dome Is Already in the Bank

⚡ Claude’s Take

The author’s own independent opinion and general information — not investment advice. The analysis in Sections 1–15 below is deliberately position-free and carries no price target; this opening block is the single place a view is expressed.

Verdict: HOLD / AVOID-here for a new position — a genuinely good business at a genuinely bad entry price. Not a short. I’d want a re-rating into roughly the high-$20s–mid-$30s (≈20–25x forward EBITDA) before the risk/reward turns.

Karman is a better business than the average small-cap defense name: it sits on ~130 mostly sole- or single-source programs where re-qualification is slow and costly, so its content tends to stay designed-in for the multi-decade life of a missile or launch program. That is a real, financially-visible moat — it shows up as 40%+ gross margins, a book of business ~90% covered by backlog, and pricing power on replenishment volumes. Layer on a genuinely generational demand backdrop (munitions restock, Golden Dome, hypersonics, the FY27 budget’s proposed 3–8x jumps on SM-6/PrSM/THAAD/PAC-3, submarine funding +30%, and a booming commercial-space launch cadence) and you can see why the stock quadrupled from its $30 IPO to $115 inside a year.

The problem is entirely price and plumbing. Even after a ~57% fall from the January 2026 peak, at ~$50 you are paying ~34x forward (FY26) EBITDA, ~10x forward sales, and ~100x forward GAAP earnings for a company whose returns on invested capital are only ~5%, whose GAAP EBITDA is ~26% lower than the “Adjusted” number it markets, whose tangible equity is negative, and which burned cash at the operating line in FY2025 (CFO −$22M, FCF −$42M) as unbilled receivables ballooned. Roughly half the headline growth is bought, not organic; the sponsor (Trive) is actively distributing stock; and net debt sits near 4x EBITDA. This is a momentum-unwind that has further to prove before it is “cheap”: the market is underwriting a decade of Golden Dome, flawless serial-acquisition integration, and a working-capital/FCF turn — all at once, up front. Framing: quality-growth-at-a-punitive-price / late-stage momentum name, not a value opportunity. Conviction: medium. What flips me bullish: two to three quarters of genuine FCF conversion (unbilled receivables turning to cash) alongside sustained ~30% organic growth. What flips me bearish: an integration stumble, a working-capital blow-out, a major-program cut, or continued sponsor overhang dragging it toward the ~20x peer multiple — which from here is ~30–40% of downside. Catchy tag: “The moat is real; the price already spent the whole decade.”

📈 Stock Price Action — Five-Year Event Map

Karman has less than eighteen months of trading history (IPO 2025-02-13), so this is a full-life map rather than a five-year one. In plain numbers: the stock IPO’d at $30, ran nearly fourfold to a peak close of $115.29 (2026-01-28), then round-tripped almost the entire move to a low of $44.84 (2026-06-24), and sits at $49.72 (2026-07-23) — roughly −57% off its high and about +66% above the IPO price. The 52-week range is ~$45–$115. It is, in factor terms, a high-beta (~1.6) space/defense momentum vehicle that led on the way up and led on the way down.

Cycle narrative: (1–2) the IPO landed into a soft tape and drifted; (3) the fundamental story — record quarters, backlog growth, and a munitions-restock thesis — took hold through mid-2025; (4) it then went vertical as Karman was swept into the late-2025/early-2026 “space and Golden Dome” momentum trade (it was named to Morgan Stanley’s space list), reaching a valuation (>90x EV/EBITDA, >20x sales) that discounted years of flawless execution; (5) the air came out on nothing company-specific so much as multiple compression, compounded by the May 2026 sponsor-led secondary (14M shares, ~$46) and post-lock-up supply; (6) the recent stabilization is partly technical — S&P SmallCap 600 inclusion forced index buying — layered on continued good news flow (a first international acquisition and fresh contract awards). The price move is FACT; the attributed causes are INTERPRETATION cross-referenced to earnings dates, 8-Ks, and the news feed.

1. Executive Summary

Karman Holdings (d/b/a Karman Space & Defense) is a ~$470M-revenue (FY2025), Huntington Beach–based merchant supplier of mission-critical, integrated subsystems — payload protection and deployment systems (fairings/shrouds/separation), aerodynamic interstage structures, and propulsion systems (solid rocket motors, nozzles, ablatives, safe-and-arm) — sold to the prime contractors and launch providers behind U.S. missile, missile-defense, hypersonic, maritime, and space programs. It was assembled from 2020 onward by private-equity sponsor Trive Capital via a “buy, build, and integrate” roll-up (AEC + AMRO, then AAE, Systima, and a widening cadence of bolt-ons), IPO’d in February 2025 at $30, and now supports 130+ programs across ~80 customers with roughly a third of revenue in each of its three legacy end markets, plus a new fourth (Maritime Defense).

The business is genuinely good. Its content is largely sole- or single-sourced and qualification-locked: once Karman is designed into a program and delivering to spec, the cost and schedule of re-qualifying an alternative supplier make displacement unlikely across the multi-decade life of a missile or launch platform. That shows in 40%+ gross margins (rising), backlog of >$1B (up 61% YoY), ~90% forward-revenue visibility, and demonstrated pricing/volume leverage as customers restock munitions. The demand backdrop is arguably the best in a generation: munitions replenishment, Golden Dome, hypersonics, submarine build-rates, counter-UAS, and a rising commercial-space launch cadence, with the FY27 budget request proposing multi-fold procurement increases on Karman-content programs.

The problems are financial and structural. Returns on invested capital are only ~5% against a balance sheet that is ~58% goodwill and intangibles with negative tangible equity; GAAP EBITDA runs ~26% below the “Adjusted” figure the company leads with; FY2025 operating cash flow was negative (−$22M) and free cash flow was −$42M as unbilled receivables surged; net debt is ~4x EBITDA; and roughly half of the eye-catching ~50%+ FY2026 growth is inorganic. The sponsor is actively selling. And after a spectacular IPO-to-peak quadruple and a ~57% unwind, the stock still trades at ~34x forward EBITDA and ~10x forward sales — a top-of-peer-group multiple that already capitalizes years of the secular tailwind. The investment question is not whether Karman is a good company (it is) but whether a good company bought at a great multiple, funded with debt and working capital, and dependent on continuous M&A can convert its backlog into cash and its scale into returns fast enough to justify the price. This memo takes no position; the analysis that follows argues that valuation, cash conversion, and leverage — not demand — are where this thesis will be won or lost.

2. Business Overview

Karman designs, tests, manufactures, and sells highly-engineered integrated subsystems that sit between raw components and the finished missile, interceptor, or launch vehicle. It is a merchant supplier to the primes — it does not build the weapon or the rocket; it supplies the mission-critical structures and propulsion elements the primes (Lockheed Martin, RTX, Northrop Grumman, Boeing) and launch providers (established and emerging) integrate into their platforms. Management organizes the offering into three product families:

• Payload Protection & Deployment Systems — the “top section” of a booster, launch vehicle, or missile: fairings, shrouds, nose cones, and deployment mechanisms that protect and release the payload. Full design-and-build authority on many of these.
• Aerodynamic Interstage Systems — metallic and composite structures that manage aerodynamics and enable stage separation (interstages, skirts, separation systems).
• Propulsion Systems — integrated solid rocket motors and supporting subsystems, critical subsystems for liquid-fueled motors, launch systems, ablative composites, nozzles, and solid-propellant-driven actuators (safe-and-arm, energetics).

These map onto end markets that in FY2025 were nearly evenly split (a deliberate diversification):

• Hypersonics & Strategic Missile Defense (~32%) — larger-diameter strategic programs and interceptors; the highest-priority, longest-cycle work.
• Tactical Missiles & Integrated Defense Systems (~31.5–36%) — smaller-diameter tactical rockets/missiles and launchers (anti-armor, air-to-air, anti-ship, surface-to-air), plus counter-UAS and loitering-munition launch systems and GMLRS content.
• Space & Launch (~37%) — payload protection, interstage, and propulsion content across traditional and emerging launch providers, plus NASA work (SLS/Orion on Artemis II, a CLPS lunar-lander integration).
• Maritime Defense Systems (new in Q1’26, ~17% of that quarter) — submarine (Columbia/Virginia-class) and LCAC content, added via the January 2026 Seemann Composites + MSC acquisition.

How it makes money. Karman sells hardware under a mix of contract types (largely firm-fixed-price and time-and-materials sub-tier work flowing from cost-plus/FFP prime contracts) tied to specific funded programs. Revenue is recognized as production progresses, which is central to its cash-flow profile (unbilled receivables build as work is performed ahead of milestone billings). Its economics are those of an engineered-components manufacturer with design authority — high gross margins from proprietary IP and qualification lock-in, meaningful engineering and G&A overhead (~300 engineers), and capital intensity that is rising as it adds capacity (a new ~200,000 sq ft Salt Lake City facility, Gulfport and Horsham expansions). Recurring-ish revenue comes from the long production tails of qualified programs; it is not subscription-recurring, but the multi-decade nature of defense/space programs and the ~90% backlog coverage give it revenue characteristics closer to recurring than to project-lumpy.

Scale and diversification. FY2025: $471.5M revenue, ~80 customers, >130 funded programs, no single program >12% of revenue — but the top three customers were 51.5% of revenue, so customer concentration is real even as program concentration is low. ~1,400–2,000 employees. HQ Huntington Beach, CA, with a national manufacturing footprint (California, Washington/Mukilteo, Pennsylvania/Horsham, Mississippi/Gulfport, Utah/Salt Lake City) plus a new UK site pending (Walker Precision, Glasgow).

Verdict: A focused, diversified-by-program merchant supplier of genuinely mission-critical hardware with attractive gross-margin economics — a real business, not a story stock in the operational sense. The complication is not what it does but how it is capitalized and priced.

3. Industry Dynamics

Karman occupies a structurally attractive niche within an attractive industry, with one important caveat about where the profit pool sits.

Demand: as good as it gets. The end markets Karman serves are riding a genuinely generational up-cycle. Munitions replenishment (Ukraine, Middle East, Indo-Pacific stockpiling) has moved from talk to multi-year framework agreements; the U.S. FY27 budget request proposes procurement increases that, per management, include a tripling of SM-6, a near-quadrupling of PrSM, and eight-fold increases in SM-3, PAC-3, and THAAD funding; “drone dominance” carries >$53B with >$14B for counter-UAS; submarine funding (Columbia/Virginia) is set to rise >30% from ~$23B (2026) to >$31B (2027); and the Space Force request includes $4.2B for launch services targeting 22 national-security launches in FY27. Golden Dome — a homeland missile-defense architecture — layers a large, multi-year new-program tailwind on top, and Karman already supplies many of its likely constituent programs. Commercial space adds a second engine: a rising launch cadence across established (SpaceX, ULA, Blue Origin) and emerging providers, plus NASA’s Artemis cadence now planned annually through and beyond 2029.

Structure: fragmented supply, few integrators. By Karman’s own description — and it is credible — the supplier base for these subsystems is a large, fragmented pool of piece-part and build-to-print shops, with few vertically-integrated design-to-production providers. That fragmentation is the source of Karman’s opportunity: it consolidates piece-part capability into integrated-system authority the primes increasingly want to outsource to simplify their own supply chains. Barriers to entry are high where it matters — qualification, security clearances (facility and personnel), specialized materials/process IP, ITAR/export control, and multi-decade program relationships — and low where it doesn’t (generic machining). The regulatory frame (DoW procurement, FAR/DFARS, CMMC cyber, ITAR) is a barrier that favors incumbents like Karman.

The caveat — profit-pool location and the prime’s make-vs-buy. The single most important structural risk is not a competitor; it is the customer. Karman’s biggest “competitor” is the prime contractor’s own insourcing decision. Primes can, and periodically do, pull subsystem work in-house when volumes scale enough to justify captive capacity, or when they want to protect margin. Karman’s defense is precisely its qualification lock-in and the primes’ current preference to outsource to move faster — but in a sustained high-volume regime, the economics of insourcing improve, and a prime that decides to build its own solid-rocket-motor or fairing capacity is a structural threat to a specific program’s economics. Marathon’s capital-cycle lens is worth applying here: high returns and booming demand attract capital, and the current munitions/space boom is drawing new solid-propellant and composite capacity (including from primes and from other PE-backed roll-ups). The very tailwind that makes Karman attractive also invites the supply response that erodes niche pricing power over time.

Verdict: Structurally good industry, good niche, with a real medium-term supply-response risk. The demand side is A-rated for the next several years; the durability of niche economics past this cycle is the open question.

4. Competitive Position

The moat, named: Karman’s advantage is best described in Greenwald’s taxonomy as customer captivity (switching costs) reinforced by intangibles (qualification, IP, clearances) and a modest scale/integration advantage — not network effects, not a classic low-cost position. The mechanism is concrete and financially testable:

1. Qualification lock-in. Once a supplier is qualified on a defense/space program and delivering to spec, re-qualifying an alternative is lengthy, costly, and risk-laden — customers rarely do it absent a quality failure. Karman’s content is designed into the production specification, often because it engaged early in the development cycle. This is the core of the moat: it converts a one-time design win into a multi-decade annuity across the program’s production life.
2. Sole/single-source positions. A “significant portion” of revenue (sell-side estimates ~87% of a prior-year base) sits in sole- or single-source positions — i.e., Karman is the only or the preferred qualified source. That is the direct financial signature of the switching-cost moat and the source of pricing power on replenishment volumes.
3. Integrated design-to-production (“concept-to-production”). Few competitors offer full-system design authority plus scaled manufacturing. Primes value a supplier who can own the subsystem end-to-end and simplify their supply chain. Karman’s ~300 engineers and in-house test/qual capability are the barrier that a build-to-print shop cannot easily replicate.
4. IP stack. Design IP (system-level authority), Proprietary IP (patented energetics, safe-and-arm, advanced materials), and Process IP (manufacturing methods for nozzles, spun-form shrouds, propellant-driven actuators). Combined, these raise the replication cost.

Pressure-testing it. The moat is real but I would size it as moderate, not fortress-wide, for three reasons. First, the make-vs-buy threat above: the moat holds against other merchant suppliers far better than against a prime that chooses to insource. Second, program-level, not franchise-level, durability: the annuity is only as durable as each program; a cancelled or de-scoped program (a real risk in any budget) takes its content annuity with it, though the 130-program spread mitigates single-program loss. Third, the returns test fails at the corporate level even if it passes at the program level: a genuine wide moat should throw off high returns on capital, but Karman’s ROIC is only ~4.8% (FY25) — because the price paid to assemble the platform (goodwill + intangibles of $638M) sits in the denominator. The moat generates excellent unit economics (40%+ gross margin) that are diluted to mediocre enterprise returns by acquisition purchase accounting and leverage. That is the central tension: Karman has a good business but has not yet demonstrated it can earn a good return on the capital deployed to own it.

Versus peers. Against pure build-to-print machining shops, Karman clearly wins on differentiation and margin. Against other integrated defense-component names — Mercury Systems (its closest factor-peer), Moog, Woodward, HEICO’s flight-support model, Ducommun, and PE-backed propulsion roll-ups (e.g., Ursa Major, X-Bow, and legacy Aerojet-now-L3Harris capacity) — Karman is smaller, faster-growing, more leveraged, and earlier in proving through-cycle returns. HEICO is the aspirational comp (a serial acquirer of niche aerospace parts that does earn high returns and generates cash); Karman is priced richer than HEICO on EBITDA while earning far lower ROIC and negative FCF — a demanding setup.

Verdict: A real, program-level switching-cost moat with strong unit economics, but enterprise-level returns that do not yet corroborate a durable franchise. Durable advantage on individual programs; “prove-it” at the corporate-return level.

5. Growth History and Forward Opportunities

History — fast, and accelerating. Revenue compounded from $226.3M (2022) → $280.7M (2023, +24%) → $345.3M (2024, +23%) → $471.5M (2025, +36.6%), i.e., a ~28% three-year CAGR that accelerated into 2025 and again into 2026 (Q1’26 +51%). This is a blend of (a) strong organic growth on rising program volumes and content gains, and (b) a steady cadence of acquisitions (AAE, Systima historically; MTI and ISP in Q2’25; Seemann Composites + MSC in Q1’26; Walker Precision pending). Management characterizes FY2026 growth as roughly half organic, half inorganic — an important qualifier the headline number obscures.

Quality of the growth — mixed. The organic component is high-quality: it is volume-and-content growth on qualified, sole/single-source programs with pricing power, not discounting. Gross margin rose through the growth (35.8%→40.3%), which is the signature of good growth — scale and mix improving unit economics rather than growth bought with price. Q1’26 organic growth was broad-based (Hypersonics +19%, Space +29%, Tactical +25%). That is genuinely impressive and rare.

The inorganic half is lower-quality by nature: it is capability-and-revenue bought with debt and equity, carrying integration risk and diluting returns via purchase accounting. It is not “bad” — the deals are close adjacencies at reportedly consistent multiples — but a 54% growth rate that is half-acquired should be mentally discounted toward a ~25–30% organic run-rate when thinking about durable compounding and, critically, when valuing the business (you cannot pay a pure-organic multiple for half-bought growth).

Forward opportunities.

• Backlog and demand commitments: >$1B backlog (+61% YoY) with ~90% coverage of FY26 guidance, plus $1B+ of multi-year (4–7yr) contingent demand commitments from the four largest customers — a new, higher-visibility layer that supports the FY27+ ramp (though “contingent” on the customers’ own end awards).
• Program ramps: the FY27 budget’s proposed multi-fold increases on SM-6/PrSM/THAAD/PAC-3, GMLRS, counter-UAS launchers, and submarine content flow directly to Karman-qualified positions.
• Golden Dome: a potential multi-year new-program engine where Karman already has content on likely constituent programs.
• Space: rising launch cadence (all major U.S. providers), Artemis annual missions, and commercial-space growth — the highest-multiple, highest-optionality piece.
• M&A runway: guided 1–2 deals/year at similar multiples; the fragmented supplier base offers a long consolidation runway (Walker adds a European missile-supply-chain foothold).
• Capacity: Salt Lake City (~200k sq ft, initial output Q4’26), Gulfport, Horsham — capacity is being installed ahead of demand, which supports share capture but pressures near-term FCF.

Verdict: High-quality organic growth wrapped in a debt-funded acquisition machine. The secular runway is real and long; the question for a buyer is how much of a decade of it is already in the price (Section 10), and whether the capacity and working-capital build convert to cash (Section 6).

6. Financial Quality

This is where the enthusiasm meets the balance sheet, and where an institutional reader should slow down.

Income statement — strong margins, thin bottom line. FY2025: revenue $471.5M; gross profit $190.0M (40.3% margin, up from 38.3%); operating income $72.9M (15.5%); GAAP EBITDA $115.7M (24.5%); non-GAAP Adjusted EBITDA $145.3M (30.8%); net income $17.4M (3.7%); diluted EPS $0.13. The gross-margin trend is the best number in the model — 35.8%→37.6%→38.3%→40.3% over four years is evidence of pricing power and mix, exactly what the moat thesis predicts. But note the funnel from EBITDA to net income: $44.6M of interest expense (leverage) and a high effective tax rate crush pretax income to $32.5M and net income to $17.4M. The business is profitable operationally but the equity earnings are thin and highly sensitive to rates and leverage.

The Adjusted-EBITDA gap — a quality-of-earnings flag. Adjusted EBITDA ($145.3M) is ~26% above GAAP EBITDA ($115.7M) — a ~$30M wedge of add-backs (acquisition/transaction costs, sponsor/management items, equity comp, non-recurring integration). Add-backs are normal for a serial acquirer, but a 26% gap is large, it is recurring (there is always a next deal to add back), and every valuation multiple the company and sell-side quote is on the flattering number. On GAAP EBITDA the leverage and valuation both look materially worse (net debt/GAAP-EBITDA ~4.0x; EV/GAAP-EBITDA ~63x trailing). Insist on the GAAP figure for leverage and valuation discipline.

Cash flow — the single biggest concern. FY2025 operating cash flow was NEGATIVE −$22.1M, and free cash flow was −$42.5M, despite $17.4M of net income and $115.7M of GAAP EBITDA. The driver: a −$93.3M working-capital build, of which unbilled receivables/AR consumed ~$67.4M. In a percentage-of-completion revenue model, fast growth mechanically builds unbilled receivables (you perform work before you bill milestones) — so some of this is “good” growth-related build. But the magnitude is such that Karman is, at present, a cash-consuming growth machine: it funds its working capital and its acquisitions and its capacity with debt and equity, not with its own cash generation. FY2024 CFO was positive ($26.6M) and FY2026 should improve as billings catch up — but until Karman demonstrates sustained positive operating cash flow and FCF, the “high-margin compounder” narrative is unproven at the level that matters (cash). Q1’26 CFO was ~breakeven ($0.2M) with FCF still negative (−$7M capex).

Balance sheet — leveraged and intangible-heavy. At 12/31/25: cash $34.0M; total debt $587M; net debt $465M; net debt/EBITDA ~4.0x (mgmt targets ~3.0x by YE26 on the Adjusted number). By Q1’26, total debt had risen to $758M (funding Seemann/MSC), at SOFR+2.75% — so interest expense is both large and floating-rate-exposed. Goodwill ($352.5M) + intangibles ($285.9M) = $638.4M, ~58% of total assets; tangible common equity is negative (tangible BVPS −$3.27 at Q1’26). EBITDA/interest coverage is ~2.6x — adequate but not comfortable, and thinner on a cash basis given negative FCF. The current ratio (3.3x) looks healthy, but that is inflated by the very unbilled receivables that are not converting to cash.

Returns — mediocre at the enterprise level. ROIC ~4.8% (FY25, down from 8.9% in FY24 as the acquired-capital base grew), ROA ~1.8%, ROE flattered by the thin/negative tangible equity base. A business with 40% gross margins should earn high returns; that it earns ~5% is the arithmetic of paying up for acquisitions and carrying leverage. Economics improve with scale at the unit level (gross margin), but have not yet improved returns on the capital deployed.

Verdict: Excellent gross-margin unit economics; poor cash conversion and mediocre returns on capital. The FY2025 negative operating cash flow, the 26% Adjusted-vs-GAAP EBITDA gap, and the negative tangible equity are the three facts a bullish narrative most conveniently omits. Do economics improve with scale? At the margin line, yes; at the cash-and-returns line, not yet demonstrated.

7. Capital Allocation

Karman is, in essence, a private-equity capital-allocation machine now operating in public markets, and it should be judged as one.

Use of proceeds / financing. The February 2025 IPO raised ~$155M of primary equity, used substantially to pay down debt (a sensible de-lever at IPO). Since then, the company has re-levered to fund M&A: debt rose from $587M (YE25) to $758M (Q1’26) to fund Seemann/MSC. The financing pattern is classic sponsor-roll-up: use cheap-ish leverage plus periodic equity to buy EBITDA, then de-lever via growth. It works while multiples are high and credit is open; it is pro-cyclical and rate-sensitive.

M&A — the core capital-allocation activity. Karman was built by acquisition and continues to acquire 1–2 targets/year “at similar multiples as past transactions.” The deals are disciplined in the sense that they are close adjacencies (advanced materials, propulsion, maritime, now European missile supply via Walker for $94M) at reportedly consistent (undisclosed but “reasonable”) multiples, and integration appears to be executed competently (margins have held/risen through the deals). The risk is threefold: (i) serial-acquisition arithmetic — buying at, say, 8–12x EBITDA while the stock trades at 34x forward is accretive to per-share value if integration holds, but it steadily builds goodwill and dilutes ROIC; (ii) integration risk compounds — each deal adds sites, systems, and cultures; a single bad deal or a botched integration in a levered structure is disproportionately damaging; (iii) dependence — roughly half of growth is inorganic, so the equity story requires continuous deal-making, which is not fully within management’s control (pipeline, price competition from other PE roll-ups).

Buybacks/dividends: none of note (a token historical distribution pre-IPO). Appropriately, all capital goes to growth and de-levering; a company burning FCF should not be returning capital.

Insider behavior and the sponsor overhang. This is a negative signal to weigh honestly. Insider Form 4 activity in 2026 is grants (code A / RSUs) — routine compensation, not discretionary open-market purchases. There are no conviction insider buys. Meanwhile, the sponsor (Trive/TCFIII Spaceco) executed a secondary offering in May 2026 (~14M shares at ~$46) — i.e., the most-informed holder is distributing into the public float, non-dilutive to the company but a persistent supply overhang and a tell about where the smart money sees value versus price. New senior hires (CEO Jon Rambeau ex-defense-prime, CGO Doug Laurendeau ex-Lockheed) are a positive governance/operating signal — bringing prime-contractor pedigree — but they arrive with equity grants, not open-market conviction buys.

Incentive alignment. As a recent PE-sponsored IPO, expect (per the proxy) equity-heavy comp tied to growth/EBITDA metrics and a board still influenced by the sponsor. That aligns management with the growth-and-de-lever plan; it does not necessarily align them with per-share return discipline or FCF (Adjusted-EBITDA-based incentives can reward acquisitive growth that dilutes cash returns).

Verdict: Competent, disciplined deal-making; unproven return-on-capital stewardship. Management allocates capital the way a good PE sponsor does — buy adjacent EBITDA, integrate, de-lever — and has executed that well operationally. But the scorecard that matters to a long-term public shareholder (ROIC, FCF per share, per-share value net of dilution and goodwill) is not yet favorable, and the sponsor’s selling is a caution, not a confirmation.

8. Changes and Headwinds — Last ~Two Years

Strategic and structural changes.

• February 2025 IPO at $30, converting from an LLC (TCFIII Spaceco Holdings) to a C-corp — the defining event; brought public capital, disclosure, and a de-lever.
• Serial M&A cadence: MTI + ISP (Industrial Solid Propulsion), Q2 2025; Seemann Composites + MSC, January 2026 (created the new Maritime Defense end market — submarine/LCAC content — a genuine capability expansion); Walker Precision Engineering (Glasgow), agreed July 2026 for $94M — the first international acquisition, a foothold in the European missile supply chain amid EU rearmament.
• New management team: CEO Jon Rambeau joined ~April 2026 (30 years at a defense prime) — a notable upgrade in prime-contractor pedigree and public-company operating credibility; Doug Laurendeau (ex-Lockheed) as Chief Growth Officer; first Chief Information & AI Officer. A CEO transition this early in a company’s public life is itself a change to underwrite.
• $1B+ contingent demand commitments (May 2026) from the four largest customers — a new, higher-visibility contracting layer.
• S&P SmallCap 600 inclusion (July 2026) — index demand, a technical support and a maturation marker.
• Secondary offering (May 2026) — sponsor distribution / float expansion.

Headwinds and watch-items.

• Valuation reset: the ~57% drawdown from the January 2026 peak is the dominant “change” — a momentum-multiple unwind that can persist or overshoot regardless of fundamentals.
• Sponsor overhang: continued Trive selling caps upside and pressures the tape.
• Rate/leverage sensitivity: floating-rate debt (SOFR+2.75%) on ~$758M means higher-for-longer rates directly hit the thin net-income line.
• Working-capital/FCF: the unbilled-receivable build must reverse into cash for the compounder thesis to hold.
• Budget/CR risk: the FY27 procurement increases are a request, subject to appropriations, continuing resolutions, and potential compromise; program timing can slip.
• Integration risk rising with deal cadence and now cross-border complexity.

Verdict: The last ~two years strengthened the franchise (capability breadth, visibility, management) but exposed the stock (valuation excess, then reset, plus sponsor selling). Net: business trajectory improved; the equity’s risk profile is now dominated by price and cash conversion, not demand.

9. Risk Analysis (Risk Matrix)

Net risk read: the catastrophic risk is low (diversified, mission-critical, secular demand, no near-term maturity wall implied), but the distribution of outcomes is wide and skewed by valuation: the most probable adverse path is not a business collapse but a multi-quarter grind of multiple compression and/or disappointing cash conversion that de-rates the equity toward peer multiples.

10. Valuation Discussion (Embedded Expectations)

Where it trades. At $49.72 (2026-07-23) on ~132.5M shares, market cap ≈ $6.6B; with Q1’26 net debt ~$684M, EV ≈ $7.27B. Against that:

Even on the forward, Adjusted figures — the most generous lens — Karman trades at ~34x EBITDA and ~10x sales. For context, high-quality defense/space growth names (KTOS, AVAV, HEICO, Mercury, Moog) generally sit in a ~15–35x forward-EBITDA band, and the highest-return, cash-generative compounders (HEICO) anchor the top of it while earning high ROIC and positive FCF. Karman sits at the top of that band while earning ~5% ROIC and negative FCF — i.e., it is priced like the best-in-class compounder without yet earning like one.

Embedded expectations — what the price requires. Reverse-engineering the ~$7.3B EV: to justify it on any reasonable forward multiple (say, a still-premium 20x EBITDA at exit), Karman needs Adjusted EBITDA to roughly double again from ~$214M toward ~$365M+ within ~3 years — implying sustained ~25–30% total growth (organic + inorganic) and margin hold and an eventual FCF turn to fund the de-lever without perpetual equity issuance. That is not impossible — the demand backdrop and backlog support high growth — but it requires everything to go right simultaneously: the budget increases to appropriate and flow, the acquisitions to keep integrating cleanly at reasonable prices, the unbilled receivables to convert to cash, and the multiple to not compress to the peer median along the way. The market is, in effect, capitalizing a decade of Golden Dome and munitions restock today, at a top-of-peer multiple, on a company that has not yet proven cash conversion.

Scenario sketch (illustrative, not a target):

• Bear — growth decelerates to ~15% as inorganic slows and a program slips; multiple compresses to ~18–20x forward EBITDA (peer median); FCF stays weak. EV re-rates toward ~$4–4.5B — meaningful downside from $7.3B.
• Base — ~25% blended growth holds a couple more years; FCF turns modestly positive; the market grants ~24–28x forward EBITDA. EV roughly holds to modestly higher; the stock is “dead money to modest” from here as growth is offset by de-rating.
• Bull — ~30%+ growth sustains, Golden Dome content converts, FCF inflects clearly positive, and the market keeps a ~32–35x multiple on a rising EBITDA base. EV compounds and the stock re-approaches prior highs.

The asymmetry from today’s price is unattractive for a new long: the bull case largely re-earns the prior peak, while the bear case is a ~40% de-rate — and the base case is roughly flat. Any own-history valuation percentile (which would flag KRMN near its “cheapest since IPO”) is misleading here and should be discarded: with <18 months of (frothy) trading history, “cheapest since IPO” tells you the stock fell 57%, not that it is cheap on any absolute or cross-sectional basis (the P/E and P/S it embeds are still 100x+ and ~10x).

Verdict (no recommendation, no target): richly valued on every absolute and cross-sectional measure; “cheap” only relative to its own brief mania. The valuation prices the demand tailwind as a certainty and the cash-conversion/returns risks as immaterial — the reverse of how this memo weighs them.

11. Variant Perception

Consensus view. The prevailing sell-side and retail narrative (multiple “Buy” notes in the news feed) is: best-in-class revenue and EBITDA growth, a mission-critical sole-source moat, ~90% backlog visibility, a generational demand cycle (munitions + Golden Dome + space), and — post-drawdown — a “the sell-off has gone too far” entry. Consensus treats the demand runway as the dominant variable and the valuation as justified by growth.

The strongest bull case. Karman is an early-innings HEICO-of-missiles: a disciplined serial acquirer of qualification-locked, sole-source niche positions in the single best-funded corner of defense/space for the next decade. Organic growth alone is ~25–30% with pricing power (rising gross margins prove it), the $1B+ demand commitments de-risk the FY27+ ramp, and as the acquired base matures and billings catch up, FCF inflects sharply positive and ROIC climbs — at which point 34x forward EBITDA looks cheap in hindsight. The new prime-pedigree management accelerates share capture. If the space segment re-rates on the SpaceX-IPO-led space trade, there is call-option upside on top.

The strongest bear case. You are paying a top-of-peer multiple (~34x fwd EBITDA, ~10x sales, ~100x earnings) for a company that (a) burns cash operationally, (b) earns ~5% ROIC, © has negative tangible equity and ~4x leverage on floating-rate debt, (d) sources ~half its growth from ever-larger debt-funded acquisitions that must keep integrating flawlessly, (e) markets an EBITDA figure 26% above GAAP, and (f) whose most-informed owner (the sponsor) is selling. The moat is real at the program level but the enterprise returns don’t corroborate it, and the prime make-vs-buy threat caps long-run niche pricing. The most likely outcome is not a blow-up but a multi-year de-rating toward peer multiples as growth normalizes and cash conversion disappoints — a ~30–40% equity de-rate even if the business does “fine.”

The 3–5 assumptions that matter most:

1. Cash conversion: does operating cash flow / FCF turn sustainably positive as billings catch up? (Bull requires yes; FY25 was negative.)
2. Organic durability: is the ~25–30% organic growth sustainable for several years, or does it fade to mid-teens as this cycle’s peak passes and supply responds?
3. Multiple: does the market keep a 30x+ EBITDA multiple, or compress it to the ~20x peer median?
4. Integration/M&A: can Karman keep buying and integrating 1–2 deals/year at reasonable multiples without a stumble in a levered structure?
5. Budget/appropriations: do the FY27 procurement increases actually appropriate and flow on schedule?

Falsification tests. Bull is falsified if: two–three consecutive quarters show continued negative/weak FCF despite revenue growth, OR organic growth decelerates below ~15%, OR an acquisition write-down/integration miss appears. Bear is falsified if: Karman posts sustained positive FCF with unbilled receivables converting to cash and holds ~25%+ organic growth for a year — proving it is a cash compounder, not just an accounting one.

Factor-positioning read. KRMN is a high-beta (~1.6) Aerospace-&-Defense/Market-factor vehicle (industry loading 1.55–1.76; R²~0.37) with a punishing recent risk-adjusted record (annualized 3-/6-month returns ~−80%, max drawdown ~−61%) — the empirical signature of a late-stage momentum name mid-unwind, not a stabilized value name. Its factor-nearest peers (Mercury Systems, Kratos, Saab, Thales) are the correct comp set and, tellingly, none carry Karman’s valuation. The tape says: momentum has broken; the stock is being re-priced from “space-trade darling” toward “defense-component supplier,” and that re-rating may not be finished. This is evidence for the bear’s “de-rating, not blow-up” framing and against the consensus “sell-off has gone too far” call — the drawdown corrected an extreme, it did not necessarily create value.

12. Fact vs. Interpretation Table

13. Open Questions

1. Cash conversion cadence: What is the expected quarterly path of unbilled-receivable conversion, and when does management commit to sustained positive FCF? (FY25 was negative; the thesis hinges on this.)
2. Organic vs. inorganic, disaggregated: What is the pure-organic growth rate excluding all acquisitions, by end market, over the last 8 quarters?
3. M&A multiples paid: What EBITDA multiples has Karman actually paid (MTI/ISP, Seemann/MSC, Walker)? Accretion math and ROIC trajectory depend on it.
4. Adjusted-EBITDA bridge: What exactly comprises the ~$30M of add-backs, and how much is genuinely non-recurring vs. perpetual deal-related?
5. Prime insourcing exposure: Which programs / what share of revenue are most exposed to a prime’s make-vs-buy reversal, and are there contractual protections?
6. Customer concentration: Who are the top three customers (51.5% of revenue), and how concentrated is the single largest?
7. Debt terms/covenants: Maturity schedule, covenant headroom, and hedged vs. floating mix on the $758M.
8. Sponsor exit path: Trive’s remaining stake and expected sell-down schedule (overhang duration).
9. Golden Dome content: Quantified, contracted content vs. aspirational positioning.
10. CEO transition: Rationale and terms of the April 2026 CEO change so early in public life.

14. What Must Be True (Bull and Bear, each with a falsification test)

For the BULL case to be right, the following must be true:

1. Organic growth stays high (~25–30%) for multiple years — the demand cycle is durable, not peaking. Falsification: organic growth (ex-M&A) prints below ~15% in any two consecutive quarters.
2. Free cash flow inflects clearly and sustainably positive as billings catch up to production. Falsification: FCF remains negative or de-minimis for FY2026 as a whole despite ~54% revenue growth.
3. Acquisitions keep integrating cleanly at reasonable multiples, lifting (not diluting) returns over time. Falsification: a goodwill/intangible impairment, a restructuring charge, or a visible integration miss on any deal.
4. The market sustains a premium (30x+ forward EBITDA) multiple as the model de-risks. Falsification: the stock re-rates to ≤20–22x forward EBITDA (peer median) and stays there.
5. Budget increases appropriate and flow, converting the FY27 request into bookings. Falsification: a full-year continuing resolution or program cut that stalls the ramp.

For the BEAR case to be right, the following must be true:

1. The valuation compresses toward peers regardless of business performance. Falsification: the multiple holds ≥30x forward EBITDA through FY2026 on rising estimates.
2. Cash conversion stays poor, forcing continued reliance on debt/equity to fund growth and M&A. Falsification: two+ consecutive quarters of solid positive FCF with unbilled receivables declining.
3. Enterprise returns stay low (~5% ROIC) as goodwill/leverage offset unit-economic strength. Falsification: ROIC trends clearly toward double digits as the acquired base matures.
4. Sponsor selling / float supply keeps a lid on the stock. Falsification: Trive fully exits (or commits to a lock-up) and the overhang clears without a lower price.
5. The organic cycle passes and supply responds, fading niche pricing power. Falsification: gross margins keep expanding through the cycle, evidencing durable pricing power.

The two cases share a crux: does free cash flow turn, and does the multiple hold? Both are observable within 2–4 quarters — making this a thesis that will be adjudicated by cash flow statements and the tape, not by demand headlines.

15. Source Appendix

See Appendix B below for the full, dated source list. Primary sources: Karman Holdings FY2025 Form 10-K (filed 2026-04-03), Q1’26 Form 10-Q (2026-05-14), Q1’26 earnings call transcript (2026-05-12), 8-K material-event filings, DEF 14A (2026-04-08), Form 3/4 insider filings, and the S-1/424B registration documents. Quantitative data cross-checked via public financial datasets, price history, and a public factor model. All figures reconciled to SEC filings where the filing is authoritative; third-party aggregated data is labeled as such.

This analysis (Sections 1–15) carries no investment recommendation and no price target. The only view expressed anywhere in this document is in the clearly-labeled “Claude’s Take” block at the top, which is the author’s own independent opinion.

APPENDIX A — Standard Diligence Questionnaire

Karman Holdings, Inc. (NYSE: KRMN) — as of 2026-07-24

Supplemental to the memo. Fact / Interpretation / Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company? The recurring investor questions (per the Q1’26 call and sell-side notes) are: (1) the shape of the demand ramp and whether the $1B+ framework/demand commitments convert to revenue in 2026 vs. 2027+ (mgmt: mostly 2027–29 upside, small 2026 portion); (2) organic vs. inorganic growth split (mgmt: ~50/50 for FY26); (3) supply-chain readiness for the ramp; (4) M&A target profile and cadence (1–2/yr, close adjacencies, similar multiples); and (5) — from the skeptics — valuation and cash conversion. The bull/bear debate centers on whether a real sole-source moat justifies a top-of-peer multiple on a cash-burning, levered roll-up.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Revenues are at a cyclical acceleration, not a peak — the munitions-replenishment / Golden Dome / space up-cycle appears early-to-mid. GAAP earnings are structurally low (thin net margin) because leverage and purchase-accounting amortization consume operating income; the “earnings” that matter here are EBITDA and (eventually) FCF, not GAAP EPS. Driven by external environment or internal action? Both: external (defense budgets, launch cadence) sets the demand ceiling; internal action (qualification wins, capacity, M&A) captures share within it. How stable are revenues? Fact: ~90% of FY26 revenue is backlog-covered; >130 programs; no single program >12%. Revenue is more stable than a typical small-cap industrial, but concentrated by customer (top 3 = 51.5%). Outlook for products/services; how big is the market? Large and growing — missile/munitions procurement, missile defense (Golden Dome), hypersonics, submarines, counter-UAS, and commercial + government space launch, all with multi-fold FY27 budget-request increases. Domestic-led with a new international (EU) leg via Walker.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Interpretation: More competitive at the margin over time — the boom is drawing new propulsion/composite capacity and PE roll-ups, and primes can insource — but Karman’s qualified sole-source positions insulate existing programs. How profitable is the business (ROIC, ROE)? Fact: ROIC only ~4.8% (FY25), ROA ~1.8% — mediocre at the enterprise level despite 40%+ gross margins, because of acquired goodwill/intangibles and leverage. Unit economics good; capital returns not yet. How profitable is the industry; barriers to entry? Attractive niche: fragmented piece-part suppliers, few integrated design-to-production providers. Barriers = qualification, clearances, ITAR, materials/process IP, multi-decade relationships. High where it counts. Can the business be easily understood? Yes at the product level (mission-critical subsystems); the financials require care (Adjusted vs. GAAP EBITDA, negative FCF, negative tangible equity, serial-M&A accounting). Undermined by foreign low-cost labor? No — ITAR/clearance requirements and mission-criticality make offshoring largely infeasible for U.S. defense content. Do brands matter? Nature of competition? Switching costs? “Brand” = reputation/heritage/mission-success track record, which matters for qualification trust. Competition is on technical differentiation and delivery, not price. Switching costs are the core moat: re-qualification is slow and costly, so qualified sole-source content persists across a program’s life.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The qualification positions and IP/relationships have value beyond book; conversely, much of the balance sheet ($638M) is acquired goodwill/intangibles of uncertain durable value. Off-balance-sheet liabilities? Operating/finance leases (multi-year, non-cancellable facility leases; ~$88M capital-lease obligations on B/S); standard government-contractor obligations. Open question: covenant terms. How conservative is the accounting? Interpretation: Aggressive-leaning in presentation — leads with Adjusted EBITDA (26% above GAAP); POC revenue builds unbilled receivables ahead of cash. Not improper, but flattering; insist on GAAP. How CapEx-hungry? Rising: ~4.3% of sales (FY25) heading to ~5% (~$36M, FY26) as capacity is installed ahead of demand (Salt Lake City, Gulfport, Horsham).

Capital Allocation & Management

How much FCF does it generate; how is it used? Fact: FCF was negative (−$42M FY25); the business currently consumes cash, funding working capital, capex, and M&A with debt and equity. Philosophy: growth-first (organic + 1–2 acquisitions/yr), then de-lever toward ~3x. Significant acquisitions recently? Yes — MTI + ISP (Q2’25), Seemann Composites + MSC (Jan '26, created Maritime segment), Walker Precision (Glasgow, $94M, agreed Jul '26, first international). Buying back shares? No. Issuing shares to insiders? RSU grants (routine); the sponsor conducted a secondary sale (May '26). Net: no buyback, sponsor distributing, modest equity comp. Compensation / incentive alignment? Interpretation: Equity-heavy, growth/EBITDA-linked (per proxy) — aligns with the growth-and-de-lever plan but not necessarily with FCF-per-share or return-on-capital discipline. Motivations of management? New prime-pedigree CEO/CGO signal an operating upgrade; sponsor’s motivation is a successful multi-year exit (hence the distribution).

Valuation & Market Data

ADR/MLP/K-1? No — U.S. C-corp (converted from LLC at IPO), common stock on NYSE. No K-1. Dividend policy? None (appropriate for a cash-consuming growth company). How profitable; is net income diverging from cash flow? Fact: Yes, sharply — FY25 net income +$17.4M vs. operating cash flow −$22.1M, a ~$40M divergence driven by the working-capital build. This is the single most important quality-of-earnings flag.

Risks & Downside

What would cause the stock to decline? Multiple compression toward peers; weak/negative FCF persisting; a program cut or CR; an integration miss/impairment; continued sponsor selling; rate increases on floating debt. Risk of catastrophic loss? Low — diversified, mission-critical, strongly-funded demand, no implied near-term maturity wall. Total loss? Very low absent a combined demand collapse and credit event.

Recent News & Events

Has the business environment changed recently? Positively on demand (FY27 budget request; $1B+ demand commitments; Artemis cadence; EU rearmament). Structurally on the company (new Maritime segment; new CEO; first international deal; S&P SmallCap 600 inclusion). On the stock: a ~57% drawdown from the Jan-2026 peak and an ongoing sponsor secondary. Significant acquisitions / accounting changes / new markets? Acquisitions as above; new Maritime Defense end market (Q1’26); new UK footprint pending; no adverse accounting-policy change noted.

APPENDIX B — Source Appendix

Karman Holdings, Inc. (NYSE: KRMN) — Research as of 2026-07-24

All figures reconciled to SEC filings where the filing is authoritative. Third-party aggregated financial and factor datasets are labeled and used for cross-checks and price/factor context; where any disagreed with a filing, the filing governs.

Primary — SEC filings (EDGAR, CIK 0002040127)

1. Form 10-K, FY2025 (filed 2026-04-03) — business description, end markets, competition, backlog ($801.1M at 12/31/25), customer concentration (top 3 = 51.5% of revenue), risk factors, MD&A, financial statements. https://www.sec.gov/Archives/edgar/data/2040127/000204012726000014/krmn-20251231.htm
2. Form 10-K, FY2024 (filed 2025-04-10) — prior-year baseline. https://www.sec.gov/Archives/edgar/data/2040127/000095017025052639/ck0002040127-20241231.htm
3. Form 10-Q, Q1 2026 (filed 2026-05-14) — Q1 financials, debt ($758M), cash ($74M), new Maritime segment. https://www.sec.gov/Archives/edgar/data/2040127/000119312526222116/krmn-20260331.htm
4. 8-K, 2026-05-12 — Q1’26 results; $1B+ contingent demand commitments. https://www.sec.gov/Archives/edgar/data/2040127/000119312526219495/
5. 8-K, 2026-03-25 — FY2025 results.
6. DEF 14A (filed 2026-04-08) — governance, compensation, ownership. https://www.sec.gov/Archives/edgar/data/2040127/000114036126013839/
7. S-3ASR / 424B7 (2026-05-28/29) — sponsor secondary offering (14M shares, ~$46). https://www.sec.gov/Archives/edgar/data/2040127/000119312526245212/
8. S-1 / 424B4 (2025-01/02) — IPO prospectus (Corporate Conversion from TCFIII Spaceco Holdings LLC; sponsor Trive Capital; founding acquisitions AEC/AMRO/AAE/Systima).
9. Form 3 / Form 4 corpus (2025–2026) — insider transactions; 2026 activity is code “A” (RSU grants); no discretionary open-market purchases.

Primary — Company communications

10. Q1 FY2026 earnings call transcript (2026-05-12) — CEO Jon Rambeau, CFO Mike Willis, COO Jonathan Beaudoin: record Q1 ($151M rev, +51%; 42% GM; $45M adj EBITDA), raised FY26 guide ($720–735M rev; $208.5–219.5M adj EBITDA), $1B+ demand commitments, ~50/50 organic/inorganic, leverage to ~3x by YE26, capex ~5% of sales, budget-request detail (SM-6/PrSM/THAAD/PAC-3/subs/space).
11. BusinessWire / PRNewswire releases (2026) — Walker Precision Engineering acquisition ($94M, Glasgow, 2026-07-20); Northrop MK-54 torpedo award ($21.3M, 2026-07-22); S&P SmallCap 600 inclusion (2026-07-14); Horsham PA facility expansion; new executive appointments (Laurendeau CGO, Knighton CIAIO); secondary offering pricing (2026-05-28).
12. Conference presentations (2026) — William Blair Growth Stock Conference; Needham Technology/Media/Consumer Conference (transcripts via Seeking Alpha).

Secondary — quantitative datasets (third-party, for cross-check)

13. Aggregated financial dataset — income statement, balance sheet, cash flow, enterprise value, valuation multiples, credit/profitability/per-share ratios (FY2022–FY2025 annual + quarterly), all reconciled to the underlying SEC filings. EV recomputed to ~$7.27B at the 2026-07-23 price.
14. Price history — daily OHLCV (IPO 2025-02-13 → 2026-07-23); used for the price-action event map (peak $115.29 on 2026-01-28; low $44.84 on 2026-06-24; $49.72 on 2026-07-23).
15. Own-history valuation percentiles — composite ~8.96 percentile — used with the explicit caveat that <18 months of trading history makes them unreliable and non-cross-sectional.
16. Factor model — stock loadings (beta ~1.6; A&D industry 1.55–1.76; R²~0.37), risk-adjusted track record (annualized 3-/6-month returns ≈ −80%, max drawdown −61%), factor-similar peers (Mercury Systems, Kratos, Saab, Thales).

Secondary — trade/financial press (context only)

17. Barron’s (Blue Origin / New Glenn supplier angle, 2026-06-05); Motley Fool, Zacks, MarketBeat (Q1 highlights, index inclusion); Seeking Alpha (multiple bull/bear notes, 2026-03 to 2026-07); defenseworld.net (13F ownership changes).

Notes

• All primary financial data is drawn from Karman’s SEC filings (10-K x2, 10-Q x4, 8-K, DEF 14A, Form 3/4, S-1/S-3), publicly available via EDGAR.
• Peer comparisons reference other publicly-traded aerospace/defense names (e.g., Kratos, AeroVironment, Mercury Systems, Moog, HEICO).